TME Pharma

The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of TME Pharma. TME Pharma disavows any obligation to update or correct the information contained in these publications.

Riecke K, Ludwig H, van Eijk L, Boyce M, Pickkers P, Macdougall I, Schwöbel F, Swinkels D.
Clinical Pharmacology, Efficacy, and Safety of the Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94).

European Iron Club
2014, Verona

Georgiev P, Lazaroiu M, Ocroteala L, Grudeva-Popova J, Gheorghita E, Vasilica M, Popescu S, Cucuianu A, Summo L, Schwoebel F, Riecke K, Ludwig H.
The Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) as Treatment of Anemia of Chronic Disease in Patients with Multiple Myeloma, Low Grade Lymphoma, and CLL: a Phase II pilot Study.

European Hematology Association
2014, Milan

Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Kruschinski A, Dümmler T, Riecke K, Ghia P, Caligaris-Cappio F, Gobbi M.
Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia.

2014, San Francisco

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Zojer N, Riecke K, Kruschinski A, Dümmler T, Foa R, Greil R, Yakoub-Agha I, Engelhardt M.
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma.

2014, San Francisco

Zboralski D, Vater A, Kruschinski A.
Comparison of Ibrutinib, Idelalisib and Olaptesed Pegol on the Immune Effector Function Mediated by Rituximab and Obinutuzumab.

2014, San Francisco

Georgiev P, Lazaroiu M, Ocroteala L, Grudeva-Popova J, Gheorghita E, Vasilica M, Popescu SM, Cucuianu A, Summo L, Schwoebel F, Riecke K, Ludwig H.
The anti-hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study.
Cancer Research. 2014, 74, 3847.
read abstract on

van Eijk LT, John AS, Schwoebel F, Summo L, Vauléon S, Zöllner S, Laarakkers CM, Kox M, van der Hoeven JG, Swinkels DW, Riecke K, Pickkers P.
Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans.
Blood. 2014, 124(17), 2643-6.
read article on

Steinbicker AU.
Comment on van Eijk et al
A novel treatment of anemia of inflammation.

2014, 124(17), 2618-19.
read comment on

Roccaro et al.
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy.
Cell Reports. 2014, 9(1), 118-28.
read article on

Purschke WG, Hoehlig K, Buchner K, Zboralski D, Schwoebel F, Vater A, Klussmann S.
Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes Sphingosine-1-Phosphate, a central mediator of angiogenesis.

Biochemical J.
2014, 462(1), 153-62.
read article on

Jerlhag E, Ivanoff L, Vater A, Engel JA.
Peripherally circulating ghrelin does not mediate alcohol-induced reward and alcohol intake in rodents.

Alcohol Clin Exp Res.
2014, 38(4), 959-68.
read article on

Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D, Baeck C, Hittatiya K, Eulberg D, Luedde T, Kiessling F, Trautwein C, Lammers T, Tacke F.
CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis.

2014, 63(12), 1960-71.
view PubMed abstract on

Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N, Hittatiya K, Eulberg D, Luedde T, Trautwein C, Tacke F.
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice.

2014,59(3), 1060-72.
read abstract on

Yamamoto H, Qin Y, Achenbach J, Li C, Kijek J, Spahn CM, Nierhaus KH.
EF-G and EF4: translocation and back-translocation on the bacterial ribosome.

Nat Rev Microbiol.
2014, 12, 89-100.
read abstract on

Liu S-C, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, Merchant M, Zboralski D, Zöllner S, Kruschinski A, Klussmann S, Recht L, Brown JM.
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats.

2014, 16(1), 21-28.
read article on

Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA.
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.

2014, 123(7), 1032-1039.
view abstract on

Marasca R, Maffei R.
Comment on Hoellenriegel et al
NOX-A12: mobilizing CLL away from home.

2014, 123(7), 952-953.
read comment on

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.